RTL AdConnect & TVSquared Partner to Bring Always-On Proof of Performance to European Broadcast TV Campaigns
9.1.2020 11:00:00 EET | Business Wire | Press release
TVSquared the global leader in TV attribution, and RTL AdConnect, the international Total Video sales house of RTL Group – a leader across broadcast, content and digital – have partnered to provide RTL AdConnect’s global advertisers with always-on proof of performance across more than 150 TV channels and BVOD (broadcaster VOD) platforms throughout Europe. This marks the first time a media owner has launched a European TV attribution initiative for advertisers.
RTL AdConnect’s global advertiser base can now leverage TVSquared’s always-on attribution platform to understand the same-day performance of campaigns airing across RTL’s broadcast channels, which reach 160 million consumers in 12 countries each day. From a single platform, advertisers can evaluate TV performance by day, daypart, creative, program, station and region. Working with RTL AdConnect, they can use those insights to inform optimizations that will maximize business-specific KPIs, including sales, website traffic, search, app activity, call center/SMS response and more.
“This partnership brings together the best of TV’s reach and campaign performance,” said Stéphane Coruble, Managing Director, RTL AdConnect. “Brands that want to expand from U.S. into Europe can take advantage of RTL’s massive broadcast and digital footprint, and measure the same-day impact of those single- or multi-country campaigns via TVSquared’s global platform.”
RTL AdConnect has increased its North American presence significantly in the last two years, helping U.S. brands navigate the complex European TV ad market. Direct-to-consumer (DTC) brands have become one of RTL AdConnect’s fastest-growing customer segments as they look to grow their businesses abroad. By partnering with TVSquared, RTL provides the real-time, transparent performance analytics that digital-native DTCs have come to expect for all media channels, including TV.
“RTL AdConnect is bringing a level of transparency and accountability never before available for European TV advertisers,” said Calum Smeaton, CEO, TVSquared. “We have seen many of our U.S. DTC clients begin to explore European expansion, and this partnership is an easy and impactful way to launch into that valuable market. Whether a brand is running a campaign in one country or multiple, they can enjoy the reach TV brings, while also understanding and optimizing its direct impact on business outcomes.”
About TVSquared
TVSquared is the largest global enterprise platform for linear and digital TV attribution. TVSquared’s always-on analytics platform empowers brands, agencies, networks and publishers to quantify TV’s impact, tie TV to business outcomes and optimize ad performance across TV everywhere. Thousands of advertisers in more than 70 countries work with TVSquared to measure TV across millions of households and billions of ad impressions. Learn more at www.tvsquared.com.
About RTL AdConnect
RTL AdConnect is the international Total Video sales house of RTL Group and beyond. It provides international advertisers a simplified access to a global premium and brand-safe total video inventory ensuring that the right media decisions are made for European campaigns. Thanks to its media partners from RTL Group and beyond, RTL AdConnect reaches around 165+ million potential consumers in Europe every day. RTL AdConnect offers exclusive solutions around high quality content across an extensive portfolio of media partners consisting of more than 150+ TV channels, 500+ digital platforms and 30+ radio stations in 12 countries. With 360-degree solutions, RTL AdConnect supports brands on every step of the way, offering full support from start to finish, ensuring high reach, deep market insights and cross-screen solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005104/en/
Contact information
Media:
Megan Garnett Coyle
TVSquared
+1 347 603 5096
megan@tvsquared.com
Carine Jean-Jean
RTL AdConnect
+33 6 30 51 58 73
cjeanjean@rtladconnect.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
